AtriCure, Inc. filings document financial results, governance matters and capital arrangements for a Nasdaq-listed medical technology company focused on Afib, left atrial appendage management and post-operative pain management. Form 8-K reports furnish quarterly and annual results, amended financial guidance disclosures, product-revenue drivers and material definitive agreements, including an asset-based revolving credit facility involving AtriCure, LLC as a borrower.
Proxy filings cover board and shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filings also identify AtriCure common stock as registered on the Nasdaq Global Market under the symbol ATRC.
AtriCure, Inc. (ATRC) received a Rule 144 notice from officer Karl Scott Dahlquist covering potential sales of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on Nasdaq. The notice lists 9,370 common shares tied to performance shares, restricted stock, and Employee Stock Purchase Plan acquisitions.
AllianceBernstein L.P. filed an amended Schedule 13G reporting beneficial ownership of AtriCure Inc common stock. As of June 30, 2026, AllianceBernstein reported beneficial ownership of 2,768,365 shares, representing 5.5% of AtriCure’s outstanding common stock. The shares are held solely for investment purposes in client discretionary investment advisory accounts.
AllianceBernstein reported sole voting power over 2,631,027 shares and sole dispositive power over 2,737,665 shares, with an additional 30,700 shares subject to shared dispositive power and no shared voting power. AllianceBernstein is a Delaware partnership and a majority-owned subsidiary of Equitable Holdings, Inc., but states it operates under independent management and makes independent decisions from its parent.
AtriCure, Inc. director Karen Prange reported a sale of 3,564 shares of Common Stock on 2026-08-05 at $38.80 per share in a sale in open market or private transaction. Following this transaction, she directly holds 22,809 AtriCure shares.
AtriCure, Inc. director Maggie Yuen reported selling 3,500 shares of Common Stock on August 5, 2026. The shares were sold in multiple trades at prices between $38.37 and $38.43, for a weighted average price of $38.42 per share. Following this transaction, she holds 14,015 shares directly. The Rule 10b5-1 trading plan checkbox was not selected.
AtriCure, Inc. insider Karen Prange filed a notice of intent to sell 3,564 shares of common stock held through Fidelity Brokerage Services LLC on NASDAQ. These shares relate to a stock award dated May 26, 2023. AtriCure had 50,866,294 shares of common stock outstanding in connection with this notice. Over the prior three months, Prange sold 1,000 shares of common stock for $28,759.40 on May 20, 2026 and 2,000 shares for $57,188.82 on May 21, 2026.
Michael H. Carrel, President, CEO, & Director of AtriCure, Inc., reported bona fide gifts of 4,700 shares of common stock on July 30, 2026. These included 700 shares to a parent and 4,000 shares as a charitable gift, with no consideration received. He also reports indirect holdings of 14,310 shares held by his children, 2,950 shares held by a parent, and 1,000 shares held by a sibling, for which he disclaims beneficial ownership except for his pecuniary interest.
AtriCure Chief Scientific Officer Vinayak Doraiswamy sold 6,000 shares of common stock on July 28, 2026 in a sale classified as an open-market or private transaction at a weighted average price of $38.88 per share, with individual trades between $38.87 and $38.92. After this transaction, he directly holds 86,511 shares of AtriCure common stock.
AtriCure director Sven Wehrwein exercised 25,000 non-qualified stock options at an exercise price of $19.95 per share on July 28, 2026, converting them into 25,000 shares of common stock. The same day, he sold 25,000 shares at a weighted average price of $37.84 per share in multiple trades between $37.73 and $39.04. Following the exercise, no options remain outstanding under this specific grant.
AtriCure, Inc. reported that Chief Marketing & Strategy Officer Justin J. Noznesky sold 6,182 shares of common stock on July 29, 2026. The shares were sold at a weighted average price of $38.80 per share, in multiple trades ranging from $38.62 to $39.28. Following this transaction, Noznesky directly holds 100,219 shares of AtriCure common stock.